Colorectal cancer and thrombosis

Area of Science:

• Oncology
• Hematology
• Biochemistry

Background:

• Colorectal cancer (CRC) induces a hypercoagulable state, increasing the risk of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE).
• VTE significantly contributes to morbidity and mortality in CRC patients, often underestimated and exacerbated by cancer treatments.
• The incidence of VTE in cancer patients is rising, highlighting the critical need for effective management strategies.

Purpose of the Study:

• To review the challenges in managing CRC-associated VTE.
• To explore the relationship between cancer biology and the clotting system.
• To identify potential therapeutic targets and biomarkers within the clotting pathway for CRC.

Main Methods:

• Literature review of studies on CRC-associated VTE.
• Analysis of current guidelines for VTE management in cancer patients.
• Exploration of the role of tissue factor (TF) and other clotting factors in CRC.

Main Results:

• CRC-associated VTE management is complicated by high recurrence rates and increased bleeding risk with anticoagulation.
• Extended thromboprophylaxis is recommended post-CRC surgery, but its use in non-hospitalized chemotherapy patients is uncertain.
• Tissue factor (TF) plays a dual role in promoting cancer and may serve as a biomarker for VTE risk and prognosis in CRC.

Conclusions:

• The clotting system and cancer biology are intricately linked, with TF influencing cancer progression.
• Clotting factors, including TF, show potential as biomarkers for VTE risk stratification and prognostic assessment in CRC.
• The clotting system presents a promising target for novel anti-cancer therapies, including anticoagulants and TF inhibitors.